Sotorasib in Previously Treated Locally Advanced or Metastatic NSCLC Subjects With Mutated KRAS p.G12C

This study tests sotorasib, a targeted drug, in people with a specific type of lung cancer (non-small cell lung cancer, or NSCLC) that has a particular genetic mutation called KRAS G12C. It is for patients whose cancer has spread or cannot be surgically removed and who have already received prior treatment. **You may be eligible if...** - You are over 18 years old - You have locally advanced or metastatic non-small cell lung cancer with a confirmed KRAS G12C gene mutation - You have already received at least one prior cancer treatment - You are in reasonably good physical condition (able to carry out normal activity with minor effort) **You may NOT be eligible if...** - You have not yet been treated for your lung cancer - You do not have the KRAS G12C mutation - You are in poor general health Talk to your doctor to see if this trial is right for you.